RxDoctor Payments Data

Daniel Duran, MD

Family Medicine · West Grove, PANPI 1467412700

Payments from drug & device makers

$1,440in general payments, 2019–2025

Across 26 payments — averaging $55.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Irras USA, Inc.$1K
  • Novo Nordisk$188
  • AstraZeneca$43
  • Sanofi Pasteur Inc.$18
  • Teva Pharmaceuticals USA, Inc.$14

What the payments were for

  • Speaking & faculty fees$1,17782%
  • Food & beverage$26318%

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,440 in reported general payments places this provider in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$143,575
Medicare patients
431
Services billed
1,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$104,158
JardianceEmpagliflozin79$84,417
MounjaroTirzepatide69$84,391
EliquisApixaban63$53,367
XareltoRivaroxaban47$42,877
Tresiba Flextouch U-200Insulin Degludec31$29,151
RybelsusSemaglutide27$26,116
JanuviaSitagliptin Phosphate12$18,474
Tresiba Flextouch U-100Insulin Degludec20$9,026
Atorvastatin Calcium415$5,430
Rosuvastatin Calcium289$5,238
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$4,200
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$4,025
Levothyroxine Sodium344$3,556
Gabapentin213$3,484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$188$130,274127 claims
AstraZenecaSymbicort$43$3,25414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in West Grove

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →